These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465 [TBL] [Abstract][Full Text] [Related]
4. A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma. Hommer A; Thygesen J; Ferreras A; Wickstrom J; Friis MM; Buchholz P; Walt JG Eur J Ophthalmol; 2008; 18(5):778-86. PubMed ID: 18850558 [TBL] [Abstract][Full Text] [Related]
5. Anterior uveitis associated with fixed-combination latanoprost and timolol. Ornek K; Onaran Z; Turgut Y Can J Ophthalmol; 2008 Dec; 43(6):727-8. PubMed ID: 19020649 [No Abstract] [Full Text] [Related]
6. Hypertensive acute granulomatous anterior uveitis as a side effect of topical brimonidine. Clemente-Tomás R; Arciniegas-Perasso CA; Hervás-Hernandis JM; García-Ibor F; Ruiz-Del Río N; Duch-Samper AM Arch Soc Esp Oftalmol (Engl Ed); 2018 Oct; 93(10):511-514. PubMed ID: 29910082 [TBL] [Abstract][Full Text] [Related]
7. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616 [TBL] [Abstract][Full Text] [Related]
8. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. Solish AM; DeLucca PT; Cassel DA; Kolodny AH; Hustad CM; Skobieranda F J Glaucoma; 2004 Apr; 13(2):149-57. PubMed ID: 15097262 [TBL] [Abstract][Full Text] [Related]
9. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. LeBlanc RP Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. García-López A; Paczka JA; Jiménez-Román J; Hartleben C BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295 [TBL] [Abstract][Full Text] [Related]
11. Brimonidine-associated uveitis - a descriptive case series. Hopf S; Mercieca K; Pfeiffer N; Prokosch-Willing V BMC Ophthalmol; 2020 Dec; 20(1):489. PubMed ID: 33334316 [TBL] [Abstract][Full Text] [Related]
12. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Becker HI; Walton RC; Diamant JI; Zegans ME Arch Ophthalmol; 2004 Jul; 122(7):1063-6. PubMed ID: 15249377 [No Abstract] [Full Text] [Related]
13. Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma. Oztürk F; Ermiş SS; Inan UU; Aşagidag A; Yaman S J Ocul Pharmacol Ther; 2005 Feb; 21(1):68-74. PubMed ID: 15718830 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Stewart WC; Stewart JA; Day D; Sharpe ED Acta Ophthalmol Scand; 2003 Jun; 81(3):242-6. PubMed ID: 12780402 [TBL] [Abstract][Full Text] [Related]
15. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832 [TBL] [Abstract][Full Text] [Related]
16. Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye. Carrasco MA; Schlaen BA; Zárate JO Int Ophthalmol; 2013 Oct; 33(5):557-60. PubMed ID: 23224363 [TBL] [Abstract][Full Text] [Related]
17. Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features. Nguyen EV; Azar D; Papalkar D; McCluskey P J Glaucoma; 2008; 17(1):40-2. PubMed ID: 18303383 [TBL] [Abstract][Full Text] [Related]
18. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Goñi FJ; Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288 [TBL] [Abstract][Full Text] [Related]
19. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension. Frampton JE Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399 [TBL] [Abstract][Full Text] [Related]
20. Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. Sharpe ED; Henry CJ; Mundorf TK; Day DG; Stewart JA; Jenkins JN; Stewart WC Eye (Lond); 2005 Jan; 19(1):35-40. PubMed ID: 15094733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]